Seer, Inc.

Seer
Company typePublic
NASDAQ: SEER
IndustryBiotechnology
Founded2017
HeadquartersRedwood City, California
Key people
Omid Farokhzad (co-founder, CEO), Robert Langer (co-founder, chair of scientific advisory board)
Revenue$14.2 million (2024)
Number of employees
140 approx. (2024)
Websiteseer.bio

Seer, Inc. (NASDAQ: SEER) is an American biotechnology company headquartered in Redwood City, California. Established in 2017, the company develops technologies for proteomics research.[1][2]

History

Seer was founded in 2017 by Omid Farokhzad, Philip Ma, and Robert Langer, based on nanoparticle technologies developed in Farokhzad’s laboratory at Brigham and Women’s Hospital, Harvard Medical School. Early investors included Maverick Capital, aMoon Fund, Wing VC, T. Rowe Price, and Fidelity.[3][4]

In September 2020, Seer spun off PrognomiQ to focus on clinical applications, such as developing a liquid biopsy blood test for early lung cancer detection. Philip Ma became President and CEO of PrognomiQ. Farokhzad serves as chair of the board of directors of PrognomiQ. Seer retains approximately 19% ownership in the company.[5][6]

On December 4, 2020, Seer completed its initial public offering, raising approximately $336.2 million in proceeds. Underwriters included J.P. Morgan, Morgan Stanley, Bank of America Securities, and Cowen.[7][8]

Seer launched the Proteograph Product Suite in January 2021, which included the SP100 automation instrument and the Proteograph RISE assay kit. In June 2023, the company introduced the Proteograph XT assay kit, which increased system throughput by 150%.[9]

In May 2025, Seer released a high-throughput version of the Proteograph Product Suite, including the Proteograph ONE Assay and SP200 Automation Instrument. The system supports processing of up to 1,000 samples per week and is designed for large-scale proteomic studies.[10][11]

Business model and operations

Seer receives revenue from the sale of products to government, academic, biopharma, and contract research organization (CRO) customers, and by providing proteomics services through its Seer Technology Access Center (STAC) in Redwood City and Bonn, Germany.

Seer has approximately 140 employees, including sales and customer support staff in the USA, Europe, and Asia. The company’s headquarters, including its research and development, is located in Redwood City, California, with additional offices in San Diego, California, and a services laboratory in Bonn, Germany. The company generated $14.2 million of revenue in 2024.[12]

Technology and product offerings

Seer's proteomics platform integrates engineered nanoparticles, automated sample preparation, and mass spectrometry. It utilizes nanoparticles with different physicochemical properties, including size, charge, and hydrophobicity, to separate and enrich proteins from biological samples, thereby addressing common issues related to dynamic range and sample complexity in proteomics. Seer's platform enables deep, unbiased proteomic analysis, allowing researchers to identify proteins associated with disease or therapeutic response without relying on prior assumptions.[13]

A 2020 study published in Nature Communications demonstrated that these nanoparticles form distinct protein coronas, enabling high-depth, parallel profiling of the plasma proteome.[14] Independent benchmark studies indicate that nanoparticle-based plasma proteomics workflows significantly enhance proteome depth and improve quantitative precision when compared to traditional neat-plasma methods. These studies report approximately 3 to 6 times more protein identifications and about twice the reproducibility in independent side-by-side experiments.[15][16]

As of 2025, 58 papers have been published related to the Proteograph, including in journals such as Nature, Nature Communications, Nature Aging, and Cell Metabolism.[15][17][18] Among these, a 2025 Nature Aging study reported the identification of more than 10,000 proteins, underscoring the Proteograph platform’s depth in studies at scale.[19]

The Proteograph Product Suite includes the Proteograph ONE Assay: a reagent system that provides for multiplexed nanoparticles for protein enrichment, the SP200 Automation Instrument: a fluid handling robotic system for preparing a large number of biological samples for mass spectrometry analysis, and the Proteograph Analysis Suite (PAS): a cloud-based software solution for large-scale proteomics data analysis.[9][11]

Partnerships

The company entered into a co-marketing and sales agreement with Thermo Fisher Scientific in November 2024 to promote the integration of Seer’s Proteograph system with Thermo Fisher’s Orbitrap mass spectrometers.[20]

In June 2025, Seer announced a collaboration with Korea University and major Korean cancer centers, including Seoul National University Hospital and Samsung Medical Center. The partnership will support a large-scale plasma proteomics study aimed at identifying blood-based biomarkers for cancers in young adults. The study will utilize Seer’s Proteograph platform and a mass spectrometer from Thermo Fisher Scientific to analyze over 20,000 plasma samples.[21]

References

  1. ^ Hale, Conor (2022-01-10). "JPM 2022: Seer launches next-generation proteomics research platform | Fierce Biotech". www.fiercebiotech.com. Retrieved 2025-10-29.
  2. ^ "Peninsula biotech tools company Seer seeks $109M just 2 months after big IPO". San Francisco Business Times. 2021-01-25. Retrieved 2025-10-29.
  3. ^ Hale, Conor (2018-12-17). "Proteome blood test developer Seer emerges with $36M in funding | Fierce Biotech". www.fiercebiotech.com. Retrieved 2025-10-29.
  4. ^ Zebr, Dane (2019-12-17). "Seer Closes $55M Series D Financing Round". GenomeWeb. Retrieved 2025-10-29.
  5. ^ Zebr, Dane (2020-09-15). "Seer Spins Out Disease Testing Firm PrognomIQ With $55M in VC Funding". GenomeWeb. Retrieved 2025-10-29.
  6. ^ Bonislawski, Adam (2024-06-07). "ASMS 2024 Sees Broad Mix of Mass Spec Launches Spanning Targeted, Discovery Applications". GenomeWeb. Retrieved 2025-10-29.
  7. ^ "Redwood City-based Seer's stock nearly tripled in IPO, valuing company at over $3B". Silicon Valley Business Journal. 2020-12-04. Retrieved 2025-10-29.
  8. ^ Beltran, Luisa. "Seer Shares Soar 197% in Trading Debut". barrons. Retrieved 2025-10-29.
  9. ^ a b "Seer Launches the Proteograph XT Assay Kit". Proteomics & Metabolomics from Technology Networks. Retrieved 2025-10-29.
  10. ^ Wolski, Chris (2025-06-03). "Proteograph Platform Enables 20,000-Sample Proteomics Study". Clinical Lab Products. Retrieved 2025-10-29.
  11. ^ a b Wolski, Chris (2025-06-03). "Proteograph Platform Enables 20,000-Sample Proteomics Study". Clinical Lab Products. Retrieved 2025-10-29.
  12. ^ "10-K". www.sec.gov. Retrieved 2025-10-29.
  13. ^ Bonislawski, Adam (2021-03-18). "Plasma Proteomics Sees Substantial Advances in Depth of Coverage, mod1". GenomeWeb. Retrieved 2025-10-29.
  14. ^ Blume, John E.; Manning, William C.; Troiano, Gregory; Hornburg, Daniel; Figa, Michael; Hesterberg, Lyndal; Platt, Theodore L.; Zhao, Xiaoyan; Cuaresma, Rea A.; Everley, Patrick A.; Ko, Marwin; Liou, Hope; Mahoney, Max; Ferdosi, Shadi; Elgierari, Eltaher M. (2020-07-22). "Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona". Nature Communications. 11 (1): 3662. doi:10.1038/s41467-020-17033-7. ISSN 2041-1723. PMC 7376165. PMID 32699280.
  15. ^ a b Ashkarran, Ali Akbar; Gharibi, Hassan; Sadeghi, Seyed Amirhossein; Modaresi, Seyed Majed; Wang, Qianyi; Lin, Teng-Jui; Yerima, Ghafar; Tamadon, Ali; Sayadi, Maryam; Jafari, Maryam; Lin, Zijin; Ritz, Danilo; Kakhniashvili, David; Guha, Avirup; Mofrad, Mohammad R. K. (2024-11-07). "Small molecule modulation of protein corona for deep plasma proteome profiling". Nature Communications. 15 (1): 9638. doi:10.1038/s41467-024-53966-z. ISSN 2041-1723. PMC 11544298. PMID 39511193.
  16. ^ Jiang, Yuming; Meyer, Jesse G. (2024). "Rapid Plasma Proteome Profiling via Nanoparticle Protein Corona and Direct Infusion Mass Spectrometry". Journal of Proteome Research. 23 (8): 3649–3658. bioRxiv 10.1101/2024.02.06.579213. doi:10.1021/acs.jproteome.4c00302. PMID 39007500.
  17. ^ Olinger, Bradley; Banarjee, Reema; Dey, Amit; Tsitsipatis, Dimitrios; Tanaka, Toshiko; Ram, Anjana; Nyunt, Thedoe; Daya, Gulzar N.; Peng, Zhongsheng; Shrivastava, Mansi; Cui, Linna; Candia, Julian; Simonsick, Eleanor M.; Gorospe, Myriam; Walker, Keenan A. (July 2025). "The secretome of senescent monocytes predicts age-related clinical outcomes in humans". Nature Aging. 5 (7): 1266–1279. doi:10.1038/s43587-025-00877-3. ISSN 2662-8465. PMC 12276915. PMID 40461807.
  18. ^ van Rosmalen, Laura; Zhu, Jiaoyue; Maier, Geraldine; Gacasan, Erica G.; Lin, Terry; Zhemchuzhnikova, Elena; Rothenberg, Vince; Razu, Swithin; Deota, Shaunak; Ramasamy, Ramesh K.; Sah, Robert L.; McCulloch, Andrew D.; Hut, Roelof A.; Panda, Satchidananda (2024-09-03). "Multi-organ transcriptome atlas of a mouse model of relative energy deficiency in sport". Cell Metabolism. 36 (9): 2015–2037.e6. doi:10.1016/j.cmet.2024.08.001. hdl:11370/fd819b4b-0922-4aca-98ca-c68f27dc074c. ISSN 1550-4131. PMID 39232281.
  19. ^ Mason, Christopher E.; Green, James; Adamopoulos, Konstantinos I.; Afshin, Evan E.; Baechle, Jordan J.; Basner, Mathias; Bailey, Susan M.; Bielski, Luca; Borg, Josef; Borg, Joseph; Broddrick, Jared T.; Burke, Marissa; Caicedo, Andrés; Castañeda, Verónica; Chatterjee, Subhamoy (August 2024). "A second space age spanning omics, platforms and medicine across orbits". Nature. 632 (8027): 995–1008. doi:10.1038/s41586-024-07586-8. ISSN 1476-4687. PMC 12366838. PMID 38862027.
  20. ^ Thomas, Uduak (2024-11-10). "Seer Showcases Deep Proteomics Capabilities, Announces Co-Marketing Deal with Thermo Fisher Scientific". GEN - Genetic Engineering and Biotechnology News. Retrieved 2025-10-29.
  21. ^ "Korea University partners with US-based Seer to develop AI-driven diagnostics for cancers in young adults". www.biospectrumasia.com. Retrieved 2025-10-29.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.